|
1
|
Raphael Waly S, Yangde Z and Yuxiang C:
Hepatocellular carcinoma: Focus on different aspects of management.
ISRN Oncol. 2012:4216732012.PubMed/NCBI
|
|
2
|
Mazzola A, Costantino A, Petta S,
Bartolotta TV, Raineri M, Sacco R, Brancatelli G, Cammà C and
Cabibbo G: Recurrence of hepatocellular carcinoma after liver
transplantation: An update. Future Oncol. 11:2923–2936. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Orang Valinezhad A, Safaralizadeh R and
Kazemzadeh-Bavili M: Mechanisms of miRNA-mediated gene regulation
from common downregulation to mRNA-specific upregulation. Int J
Genomics. 2014:9706072014.PubMed/NCBI
|
|
5
|
Bushati N and Cohen SM: microRNA
functions. Annu Rev Cell Dev Biol. 23:175–205. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer.
94:776–780. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mao B and Wang G: MicroRNAs involved with
hepatocellular carcinoma (Review). Oncol Rep. 34:2811–2820. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Giordano S and Columbano A: MicroRNAs: New
tools for diagnosis, prognosis, and therapy in hepatocellular
carcinoma? Hepatology. 57:840–847. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang SH, Zhang WJ, Wu XC, Weng MZ, Zhang
MD, Cai Q, Zhou D, Wang JD and Quan ZW: The lncRNA MALAT1 functions
as a competing endogenous RNA to regulate MCL-1 expression by
sponging miR-363-3p in gallbladder cancer. J Cell Mol Med.
20:2299–2308. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hu F, Min J, Cao X, Liu L, Ge Z, Hu J and
Li X: MiR-363-3p inhibits the epithelial-to-mesenchymal transition
and suppresses metastasis in colorectal cancer by targeting Sox4.
Biochem Biophys Res Commun. 474:35–42. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang PF, Sheng LL, Wang G, Tian M, Zhu
LY, Zhang R, Zhang J and Zhu JS: miR-363 promotes proliferation and
chemo-resistance of human gastric cancer via targeting of FBW7
ubiquitin ligase expression. Oncotarget. 7:35284–35292.
2016.PubMed/NCBI
|
|
14
|
Chapman BV, Wald AI, Akhtar P, Munko AC,
Xu J, Gibson SP, Grandis JR, Ferris RL and Khan SA: MicroRNA-363
targets myosin 1B to reduce cellular migration in head and neck
cancer. BMC Cancer. 15:8612015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang R, Li Y, Dong X, Peng L and Nie X:
MiR-363 sensitizes cisplatin-induced apoptosis targeting in Mcl-1
in breast cancer. Med Oncol. 31:3472014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou P, Huang G, Zhao Y, Zhong D, Xu Z,
Zeng Y, Zhang Y, Li S and He F: MicroRNA-363-mediated
downregulation of S1PR1 suppresses the proliferation of
hepatocellular carcinoma cells. Cell Signal. 26:1347–1354. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ou Y, Zhai D, Wu N and Li X:
Downregulation of miR-363 increases drug resistance in
cisplatin-treated HepG2 by dysregulating Mcl-1. Gene. 572:116–122.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang H, Zheng W, Shuai X, Chang RM, Yu L,
Fang F and Yang LY: MicroRNA-424 inhibits Akt3/E2F3 axis and tumor
growth in hepatocellular carcinoma. Oncotarget. 6:27736–27750.
2015.PubMed/NCBI
|
|
19
|
Liu Y, Zhang W, Liu K, Liu S, Ji B and
Wang Y: miR-138 suppresses cell proliferation and invasion by
inhibiting SOX9 in hepatocellular carcinoma. Am J Transl Res.
8:2159–2168. 2016.PubMed/NCBI
|
|
20
|
Liu S, Liu K, Zhang W, Wang Y, Jin Z, Jia
B and Liu Y: miR-449a inhibits proliferation and invasion by
regulating ADAM10 in hepatocellular carcinoma. Am J Transl Res.
8:2609–2619. 2016.PubMed/NCBI
|
|
21
|
Zhang W, Liu K, Liu S, Ji B, Wang Y and
Liu Y: MicroRNA-133a functions as a tumor suppressor by targeting
IGF-1R in hepatocellular carcinoma. Tumour Biol. 36:9779–9788.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li X, Liu X, Fang J, Li H and Chen J:
microRNA-363 plays a tumor suppressive role in osteosarcoma by
directly targeting MAP2K4. Int J Clin Exp Med. 8:20157–20167.
2015.PubMed/NCBI
|
|
23
|
Li Y, Chen D, Li Y, Jin L, Liu J, Su Z, Qi
Z, Shi M, Jiang Z, Ni L, et al: Oncogenic cAMP responsive
element binding protein 1 is overexpressed upon loss of tumor
suppressive miR-10b-5p and miR-363-3p in renal cancer. Oncol Rep.
35:1967–1978. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Qiao J, Lee S, Paul P, Theiss L, Tiao J,
Qiao L, Kong A and Chung DH: miR-335 and miR-363 regulation of
neuroblastoma tumorigenesis and metastasis. Surgery. 154:226–233.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen Y, Lu X, Wu B, Su Y, Li J and Wang H:
MicroRNA 363 mediated positive regulation of c-myc translation
affect prostate cancer development and progress. Neoplasma.
62:191–198. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rady B, Chen Y, Vaca P, Wang Q, Wang Y,
Salmon P and Oberholzer J: Overexpression of E2F3 promotes
proliferation of functional human β cells without induction of
apoptosis. Cell Cycle. 12:2691–2702. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ginsberg D: E2F3-a novel repressor of the
ARF/p53 pathway. Dev Cell. 6:742–743. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gao Y, Li H, Ma X, Fan Y, Ni D, Zhang Y,
Huang Q, Liu K, Li X, Wang L, et al: E2F3 upregulation promotes
tumor malignancy through the transcriptional activation of HIF-2a
in clear cell renal cell carcinoma. Oncotarget. Jul 13–2016.(Epub
ahead of print). doi: 10.18632/oncotarget.10568.
|
|
29
|
Rennhack J and Andrechek E: Conserved E2F
mediated metastasis in mouse models of breast cancer and HER2
positive patients. Oncoscience. 2:867–871. 2015.PubMed/NCBI
|
|
30
|
Trikha P, Sharma N, Pena C, Reyes A, Pécot
T, Khurshid S, Rawahneh M, Moffitt J, Stephens JA, Fernandez SA, et
al: E2f3 in tumor macrophages promotes lung metastasis. Oncogene.
35:3636–3646. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zeng X, Yin F, Liu X, Xu J, Xu Y, Huang J,
Nan Y and Qiu X: Upregulation of E2F transcription factor 3 is
associated with poor prognosis in hepatocellular carcinoma. Oncol
Rep. 31:1139–1146. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xue J, Niu YF, Huang J, Peng G, Wang LX,
Yang YH and Li YQ: miR-141 suppresses the growth and metastasis of
HCC cells by targeting E2F3. Tumour Biol. 35:12103–12107. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cao T, Li H, Hu Y, Ma D and Cai X: miR-144
suppresses the proliferation and metastasis of hepatocellular
carcinoma by targeting E2F3. Tumour Biol. 35:10759–10764. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xiao F, Zhang W, Chen L, Chen F, Xie H,
Xing C, Yu X, Ding S, Chen K, Guo H, et al: MicroRNA-503 inhibits
the G1/S transition by downregulating cyclin D3 and E2F3 in
hepatocellular carcinoma. J Transl Med. 11:1952013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang Y, Chang S, Zhao Z, Hou NI, He K,
Wang X, Gao L, Wang L, Cai D, Guo BO, et al: MicroRNA-214
suppresses the proliferation of human hepatocellular carcinoma
cells by targeting E2F3. Oncol Lett. 10:3779–3784. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Su J, Wang Q, Liu Y and Zhong M: miR-217
inhibits invasion of hepatocellular carcinoma cells through direct
suppression of E2F3. Mol Cell Biochem. 392:289–296. 2014.
View Article : Google Scholar : PubMed/NCBI
|
